Keywords
Comorbilidad
Antidepresivos Fibromyalgia
Comorbidity
Antidepressants
How to Cite
Abstract
Introduction: advances in the understanding of fibromyalgia as a disease of multifactorial aetiology, with biological, psychological and social, in which psychiatric comorbidity is often justified to evaluate the efficacy and safety of treatment, especially antidepressants. Method: biomedical literature search of Medline, Ovid, Proquest, Scielo and EMBASE, crossing the expression MeSH fibromialgya with pathophysiology and clinical trial and identified the outcomes for clinical trials, systematic reviews and / or meta-analysis in Spanish or English in the past 25 years in the adult population. Results: we selected articles thrown by our search, considered clinically relevant for methodological quality and results in terms of safety, efficiency and effectiveness. Conclusions: the FM is a generalized disease, disabling, multifactorial etiology in which psychosocial factors and psychiatric comorbidities are keys in the development and maintenance of it. The combination of pharmacological and non pharmacological treatment remains the most important recommendation for patients with FM. Antidepressants are a useful and safe option in the treatment of FM especially tricyclic antidepressants and dual antidepressants such as duloxetine and milnacipran.
References
Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia - a review. Joint Bone Spine 2008 May;75(3):273-9. https://doi.org/10.1016/j.jbspin.2007.09.010
Yunus MB. A comprehensive medical evaluation of patients with fibromyalgia syndrome. Rheum Dis Clin North Am 2002 May;28(2):201-vi. https://doi.org/10.1016/S0889-857X(01)00002-3
Bruckle W, Zeidler H. [Fibromyalgia]. Internist (Berl) 2004 Aug;45(8):923-32. https://doi.org/10.1007/s00108-004-1224-5
Biewer W, Conrad I, Hauser W. [Fibromyalgia]. Schmerz 2004 Apr;18(2):118-24. https://doi.org/10.1007/s00482-003-0300-4
Melillo N, Corrado A, Quarta L, D'Onofrio F, Trotta A, Cantatore FP. [Fibromyalgic syndrome: new perspectives in rehabilitation and management. A review]. Minerva Med 2005 Dec;96(6):417-23.
Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005 Aug;75: 6-21.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990 Feb;33(2):160-72.
Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis. I. A "blinded," controlled study of symptoms and tender points. Arthritis Rheum 1983 Jul;26(7): 817-24. https://doi.org/10.1002/art.1780260701
Yunus MB. Diagnosis, etiology, and management of fibromyalgia syndrome: an update. Compr Ther 1988 Apr;14(4):8-20.
Greenfield S, Fitzcharles MA, Esdaile JM. Reactive fibromyalgia syndrome. Arthritis Rheum 1992 Jun;35(6):678-81. https://doi.org/10.1002/art.1780350612
Raphael KG, Janal MN, Nayak S. Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women. Pain Med 2004 Mar;5(1):33-41. https://doi.org/10.1111/j.1526-4637.2004.04003.x
Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999 Dec;94(12):3541-6. https://doi.org/10.1111/j.1572-0241.1999.01643.x
Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis 1977;28(1):928-31.
Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am 1989 Feb;15(1):1-18.
Yunus MB. Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional spectrum syndrome. Baillieres Clin Rheumatol 1994 Nov;8(4):811-37. https://doi.org/10.1016/S0950-3579(05)80050-0
Turk DC, Okifuji A, Sinclair JD, Starz TW. Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol 1996 Jul;23(7):1255-62.
Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007 Jan;8(1):67-74. https://doi.org/10.2217/14622416.8.1.67
Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. Arthritis Rheum 2004 Mar;50(3):944-52. https://doi.org/10.1002/art.20042
Burda CD, Cox FR, Osborne P. Histocompatability antigens in the fibrositis (fibromyalgia) syndrome. Clin Exp Rheumatol 1986 Oct;4(4):355-8.
Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999 Feb;26(2):408-12.
Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxietyrelated personality traits. Arthritis Rheum 2002 Mar;46(3):845-7. https://doi.org/10.1002/art.10103
Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007 Jan;8(1):51-8. https://doi.org/10.1016/j.jpain.2006.05.014
Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003 Jun;75(1):77-82. https://doi.org/10.1016/S0165-0327(02)00025-3
Treister R, Pud D, Ebstein RP, Laiba E, Gershon E, Haddad M, et al. Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans. Pain 2009 Dec 15;147(1-3):187-93. https://doi.org/10.1016/j.pain.2009.09.001
Walker EA, Keegan D, Gardner G, Sullivan M, Katon WJ, Bernstein D. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosom Med 1997 Nov;59(6):565-71. https://doi.org/10.1097/00006842-199711000-00002
Amital D, Fostick L, Polliack ML, Segev S, Zohar J, Rubinow A, et al. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities? J Psychosom Res 2006 Nov;61(5):663-9. https://doi.org/10.1016/j.jpsychores.2006.07.003
Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007 May 15;146(10):726-34. https://doi.org/10.7326/0003-4819-146-10-200705150-00006
Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006 Jun;12(3):124-8. https://doi.org/10.1097/01.rhu.0000221817.46231.18
Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain 2006 Sep;124(1-2):117-25. https://doi.org/10.1016/j.pain.2006.04.004
Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004 Nov 17;292(19):2388-95. https://doi.org/10.1001/jama.292.19.2388
Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009 Jan 14; 301(2):198-209. https://doi.org/10.1001/jama.2008.944
Acuna C. Duloxetine for the treatment of fibromyalgia. Drugs Today (Barc ) 2008 Oct;44(10): 725-34. https://doi.org/10.1358/dot.2008.44.10.1269675
Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc ) 2008 Sep;44(9): 653-60. https://doi.org/10.1358/dot.2008.44.9.1256003
Pae CU, Marks DM, Shah M, Han C, Ham BJ, Patkar AA, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009 Nov;32(6):355-63. https://doi.org/10.1097/WNF.0b013e3181ac155b
Dryson E. Venlafaxine and fibromyalgia. N Z Med J 2000 Mar 10;113(1105):87. https://doi.org/10.1023/A:1008387132377
Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003 Nov;37(11):1561-5. https://doi.org/10.1345/aph.1D112
Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995 Sep;38(9):1211-7. https://doi.org/10.1002/art.1780380906
Arnold LM, Keck PE, Jr., Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000 Mar;41(2):104-13. https://doi.org/10.1176/appi.psy.41.2.104
Dwight MM, Arnold LM, O'Brien H, Metzger R, MorrisPark E, Keck PE, Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998 Jan;39(1):14-7. https://doi.org/10.1016/S0033-3182(98)71375-1
Ablin JN, Buskila D. Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs 2008 Mar; 13(1):53-62. https://doi.org/10.1517/14728214.13.1.53
Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007 Mar;19(2):111-7.
Dobkin PL, Sita A, Sewitch MJ. Predictors of adherence to treatment in women with fibromyalgia. Clin J Pain 2006 Mar;22(3):286-94. https://doi.org/10.1097/01.ajp.0000173016.87612.4b
Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: is there a problem? Eur J Pain 2009 Feb;13(2):115-23. https://doi.org/10.1016/j.ejpain.2008.02.010
Duncan B, White A, Rahman A. Acupuncture in the treatment of fibromyalgia in tertiary care--a case series. Acupunct Med 2007 Dec;25(4):137-47. https://doi.org/10.1136/aim.25.4.137
Valim V, Oliveira L, Suda A, Silva L, de AM, Barros NT, et al. Aerobic fitness effects in fibromyalgia. J Rheumatol 2003 May;30(5):1060-9.
Bradley LA. Cognitive-behavioral therapy for primary fibromyalgia. J Rheumatol Suppl 1989 Nov;19:131-6.
Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol 2006 Aug;2(8):416-24. https://doi.org/10.1038/ncprheum0245
Busch AJ, Schachter CL, Overend TJ, Peloso PM, Barber KA. Exercise for fibromyalgia: a systematic review. J Rheumatol 2008 Jun;35(6):1130-44.
Burckhardt CS. Nonpharmacologic management strategies in fibromyalgia. Rheum Dis Clin North Am 2002 May;28(2):291-304. https://doi.org/10.1016/S0889-857X(01)00005-9
Casale R, Cazzola M, Arioli G, Gracely RH, Ceccherelli F, Atzeni F, et al. Non pharmacological treatments in fibromyalgia. Reumatismo 2008 Jul;60 Suppl 1:59-69.
Jackel WH, Genth E. [Fibromyalgia]. Z Rheumatol 2007 Nov;66(7):579-90. https://doi.org/10.1007/s00393-007-0229-6